UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
 GSK plc (the 'Company')
Transaction notification
​
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr Hal Barron
 
b)
Position/status
Non-Executive Director
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Disposal of notional ADSs following Dr Barron's election to re-allocate funds within his GSK Executive Supplemental Savings Plan account
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
$59.1700
 
67,601.825
 
 
 
 
 
 
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-05
f)
Place of the transaction
 
N/A
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
Registered in England & Wales:
No. 3888792

Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: February 09, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc